— Know what they know.
Not Investment Advice

LFCR NASDAQ

Lifecore Biomedical, Inc.
1W: +1.1% 1M: -1.2% 3M: +49.1% YTD: -16.8% 1Y: -5.0% 3Y: -9.4% 5Y: -32.5%
$6.44
+0.00 (+0.00%)
After Hours: $6.62 (+0.17, +2.72%)
Weekly Expected Move ±27.7%
$3 $5 $6 $8 $10
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Buy · Power 58 · $244.1M mcap · 34M float · 0.906% daily turnover · Short 33% of daily vol
Credit Risk of going bust: higher than 85% of companies Debt: 38.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the second-riskiest tenth, about 1 in 87 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.50 (down 92%), Lifecore Biomedical, Inc. would be worth roughly what it owes.
Total debt $155.1M against a stock market value of $244.1M.
Distance to default 2.19 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $75.0M (short-term plus half of long-term), stock volatility 76.8%; Altman Z -0.61. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Watch 25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$244.1M
52W Range3.63-8.98
Volume441,609
Avg Volume310,410
Beta0.98
Dividend—
Analyst Ratings
4 Buy 4 Hold 0 Sell
Consensus Buy
Company Info
CEOPaul Josephs
Employees382
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date1996-02-15
3515 Lyman Boulevard
Chaska, MN 55318
US
952 368 4300
About Lifecore Biomedical, Inc.

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Recent Insider Trades

NameTypeSharesPriceDate
Kiper Christopher S A-Award 25,907 — 2026-06-04
OBUS NELSON A-Award 25,907 — 2026-06-04
Aryeh Jason A-Award 25,907 — 2026-06-04
Schechter Joshua A-Award 25,907 — 2026-06-04
Korenberg Matthew E A-Award 25,907 — 2026-06-04

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms